SGLT2 inhibitor reduces filling pressure in HFrEF patients

Reuters Health - 03/12/2020 - Twelve weeks of treatment with empagliflozin reduces filling pressure in patients with heart failure (HF) and reduced ejection fraction (HFrEF), new findings show. Patients on the sodium-glucose-cotransporter-2 inhibitor (SGLT2i) had a 2.40-mmHg reduction in pulmonary capillary wedge pressure (PCWP) during exercise, regardless of whether or not a patient had type-2 diabetes mellitus (DM), Dr. Massar Omar of Odense University Hospital in Denmark and colleagues found. "This clinically meaningful result is despite a stable, well-treated, less symptomatic (NYHA II in 83%) and euvolemic HFrEF population. Whether reduction in filling pressure would be greater in a sicker heart-failure population is speculative," Dr. Omar told Reuters Health by email. Patients with HFrEF have low cardiac output and increased left ventricular (LV) filling pressure, he and his colleagues note in the Journal of the American College of Cardiology. Several s...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 3 December, 20208 December, 2020